Samen werken, voor een psychisch gezonde jeugd

Zoeken
Generic filters
Exact matches only

Bronnen

Aman, M., De Smedt, G., Derivan, A., Lyons, B., & Findling, R. (2002). Double-blind placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intellingence. American journal of psychiatry159, 1337-1346.

Aman, M.G., Buican, B., & Arnold, L.E. (2003). Methylphenidate treatment in children with borderline IQ and mental retardation : analysis of three aggregated studies. Journal of Child and Adolescent Psychopharmacology, 13, 29-40.

Agarwal, V., Sithole, P., Kumar, S., & Prasad, M. (2001). Double-blind, placebo-controlled trial of clonidine in hyperactive children with mental retardation. Mental Retardation, 39, 259-267.

Arnold, M.E., Aman, M.G., Cook, A., Witwer, K., Hall, S.T., & Yasar, R. (2006). Atomoxetine for Hyperactivity in Autism Spectrum Disorders: Placebo-Controlled Crossover Pilot Trial. Journal of the American Academy of Child & Adolescent Psychiatry, 45, 1196-1205.

Bellinghen, M. van & Troch, C. de (2001). Ripseridone in the treatment of behavioral Distrurbance in children and adolescents with borderline intellectual functioning: Double blind, placebo-controlled Pilot trial. Journal of child and adolescent psychopharmacology, 11, 5-13.

Braam, W., Smits, M., Didden, E., Korzilius, H., Geijlswijk I. van, & Curfs, L. (2009). Exogenous melatonin for sleep problems in individuals with intellectuel disability: a meta-analysis. Developmental medicine and child neurology, 51, 340-349.

Buitelaar, J., Gaag, R.J. van der, Cohen-Kettenis, P., Melman, C. (2001). A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. Journal Clinical Psychiatry, 62, 239-248.

Coppola, G., Iervolin, G., Mastrosimone, M., La Torre, G., Ruiu, F., & Pascotto, A. (2004). Melatonine in wke-sleep disorders in children, adolescents and Young adults with mental retardation wit hor without epilepsy: a double blind, cross-over, placebo-controlled trial. Brain and development, (26) 373-376.

Correia Filho, A., Bordonese, R., Silva, T., Alvares, J., Aman, M., & Rohde, L. (2005). Comparison of risperidonea and methylphenidate for reducing ADHD in chuldren and adolescents with moderate mental retardation. Journal of the American Academy of Child & Adolescent Psychiatry, 44, 748-755.

Handen, B.L., Jonosky, J., Mcauliffe, S., Breaux, A.M., & Feldman, H. (1994). Prediction of respons to methylphenidate among children with ADHD and mental retardation. Journal of the American Academy of Child & Adolescent Psychiatry, 33, 1185-1193.

Handen, B.L., Jonosky, J., Mcauliffe, S. (1997). Long-term follow-up of children with mental retardation/borderline intellectual functioning and ADHD. Journal of Abnormal Child Psychology, 25, 287-295.

Handen, B.L. & Gilchrist, R. (2006). Practioner Review: Psychopharmacology in children and adolescents with mental retardation. Journal of Child Psychology and Psychiatry, 47,871-882.

Hellings, J., Zarcone, J., Reese, R., Valdovinos, M., Marquis, J., Fleming, K., et al. (2006). A crossover syudy of risperidone in choldren, adolescents and adults with mental retardation. Journal of Autism and Developmental Disorders, 36, 401-411.

Hellings, J., Zarcone, J., Crandall, K., Wallace, D., & Schroeder, S. (2001). Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation. Journal of Child and Adolescent Psychopharmacology, 11, 229-238.

Pearson, D.A., Santos, C.W., Casat, C.D., Lane, D.M., Jerger, S.W., Roache, J.D., et al. (2004). Treatment Effects of Methylphenidate on Cognitive Functioning in Children With Mental Retardation and ADHD, Journal of the American Academy of Child & Adolescent Psychiatry, 43, 677-685.

Pearson, D.A., Lane, D.M., Santos, C.W., Casat, C.D., Jerger, S.W., Loveland, K.A., et al. (2004). Effects of Methylphenidate Treatment in Children With Mental Retardation and ADHD: Individual Variation in Medication Response, Journal of the American Academy of Child & Adolescent Psychiatry, 43, 686-698.

Reyes, M., Croonenberghs, J., Augustyns, I., & Eerdekens, M. (2006). Long-term use of risperidone in children with disruptive behavior disorders and subaverage intelligence: Efficacy, Safety and Tolerability. Journal of Child and Adolescent Psychopharmacology, 16, 260-272.

Snyder, R., Turgay, A., Aman, M., Binder, C., Fisman, S., & Carroll, A. (2002). Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQ’s. Journal of the American Academy of Child & Adolescent Psychiatry, 41, 1026-1036.

Tyrer, P., Oliver-Africano, P., Romeo, R., Knapp, M., Dickens, S., Bouras, N., et al. (2009). Neuroleptics in the treatment of aggressive challenging behaviour for people with intellectual disabilities:a randomised controlled trial. Health Technology Assessment, 13, 1-54.

Zarcone, J., Hellings, J., Crandall, K., Reese, R., Marquis, J., Fleming, K., Shores, R., et al. (2001). Effects of ripseridone on aberrant behavior of persons with Developmental Disabilities: I. A Double-Blind crossover study Using multiple measures.American journal on mental retardation, 106, 525-538.

    Het Kenniscentrum Kinder- en Jeugdpsychiatrie maakt gebruik van cookies voor analyse van het gebruik van deze website en om de website optimaal te laten werken. Jouw bezoek blijft daarbij anoniem. Voor meer informatie, zie onze privacyverklaring

    Deze site is standaard ingesteld op 'cookies toestaan", om je de beste mogelijke blader ervaring te geven. Als je deze site blijft gebruiken zonder je cookie instellingen te wijzigen, of als je klikt op "Accepteren" hieronder, dan geef je toestemming voor het gebruik van Cookies.

    Sluiten